Breakthroughs Highlighted in Nurix's Latest Cancer Drug Research Nurix Therapeutics presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing potent brain-penetrant protein degraders targeting BTK, BRAF, and Aurora A kinase. These advances may offer new hope for patients with difficult-to-treat cancers, particularly those with central nervous system involvement, as the company advances its pipeline.12